San Francisco, California
London, United Kingdom
CURE welcomes you to a presentation featuring Dr. Thomas Steitz, Nobel Prize Laureate and co-founder of Melinta Therapeutics (formerly known as Rib-X).
The biotech industry is currently facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also address critical commercial goals that include persuasive data to satisfy the payor. At Melinta Therapeutics, commercial needs — particularly payor needs — play a major voice in its R&D strategy.
Melinta Therapeutics’ mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. Its late-stage investigational antibiotic, delafloxacin, is currently in Phase 3 development for acute bacterial skin and skin structure infections. In addition, Melinta’s RX‑04 research program is yielding new classes of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause serious hospital infections.
Host: Susan Froshauer, PhD, President and CEO, CURE
Yale's Dr. Thomas Steitz, Nobel Prize Laureate and co-founder of Melinta, will provide introductory remarks about the the company's foundation science.
Mary Szela, CEO of Melinta, and Eugene Sun, Senior Vice President of R&D, will talk through the Melinta process, indicating what worked and what didn't, and illustrating why taking a strategic and measured approach to embedding payor needs into the R&D process ensures long-term success for your company and for your lead assets.
Thomas A. Steitz, Ph.D.
Thomas A. Steitz is Sterling Professor of Molecular Biophysics and Biochemistry and Professor of Chemistry at Yale University as well as an Investigator of the Howard Hughes Medical Institute. He is the 2009 Nobel Prize Laureate in Chemistry. For the last three decades, research in the laboratory of Dr. Steitz has focused on obtaining insights into the molecular mechanisms by which the proteins and nucleic acids involved in the central dogma of molecular biology carry out gene expression from replication and recombination of the DNA genome to its transcription into mRNA followed by the various components associated with the translation of mRNA into protein. Dr. Steitz was a Co-Founder of Rib-X Pharmaceuticals, which became Melinta.
Mary Szela joined Melinta Therapeutics as director in January 2013 and was named chief executive officer in April 2013. Ms. Szela is an accomplished pharmaceutical executive with a 25-year history of consistently creating growth, generating positive organizational change and inspiring high-performing teams. Most recently, she was senior vice president of global strategic marketing and services in the Abbott Laboratories Pharmaceutical Products Group.
Eugene Sun, M.D.
Eugene Sun, M.D., joined Melinta Therapeutics in April 2013 as executive vice president, research and development. Prior to joining Melinta, Dr. Sun held multiple positions over a 17-year career at Abbott Laboratories, where he most recently served as corporate vice president, global pharmaceutical clinical development.
When & Where
CURE is the bioscience cluster of Connecticut, a diverse network of small and large life and health care sciences companies, universities, scientists, educators, students, entrepreneurs, mentors, business experts, and investors. Together we cultivate entrepreneurship, build bioscience companies, and collaborate to ensure a sustainable, high-value bioscience and healthcare community that improves our quality of life and keeps the Connecticut economy strong.